Pathstone Holdings
PTGX icon

Pathstone Holdings’s Protagonist Therapeutics PTGX Stock Holding History

Pathstone Holdings’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.46M Sell
28,187
-65
-0.2% -$6.79K 0.01% 824
2026
Q1 		$2.98M Buy
28,252
+11,811
+72% +$1.05M 0.01% 819
2025
Q4 		$1.44M Buy
16,441
+3,079
+23% +$252K 0.01% 1206
2025
Q3 		$888K Buy
13,362
+5,167
+63% +$294K ﹤0.01% 1490
2025
Q2 		$453K Buy
+8,195
New +$393K ﹤0.01% 1763

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Pathstone Holdings's PTGX Position: Q2 2026 in Review

Pathstone Holdings reduced its Protagonist Therapeutics (PTGX) stake by 0.23% in Q2 2026, selling an estimated $6.79K and leaving 28,187 shares worth $3.46M. The position accounts for 0.01% of the portfolio, ranked #824.

Pathstone Holdings first reported a position in PTGX in Q2 2025 and has held it in 5 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Pathstone Holdings held 28,187 shares of Protagonist Therapeutics worth $3.46M as of Q2 2026.
  • Pathstone Holdings sold 65 Protagonist Therapeutics shares in Q2 2026, an estimated $6.79K.
  • Protagonist Therapeutics made up 0.01% of Pathstone Holdings's portfolio in Q2 2026, its #824 holding.
  • Pathstone Holdings first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.